WallStSmart

Castle Biosciences Inc (CSTL)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 15111% more annual revenue ($57.36B vs $377.13M). NVS leads profitability with a 17.5% profit margin vs -6.1%. NVS earns a higher WallStSmart Score of 48/100 (D+).

CSTL

Avoid

34

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 6.7Quality: 8.5
Piotroski: 3/9Altman Z: 3.11

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CSTLUndervalued (+59.1%)

Margin of Safety

+59.1%

Fair Value

$79.14

Current Price

$32.75

$46.39 discount

UndervaluedFair: $79.14Overvalued
NVSSignificantly Overvalued (-67.6%)

Margin of Safety

-67.6%

Fair Value

$95.76

Current Price

$160.50

$64.74 premium

UndervaluedFair: $95.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CSTL4 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.1110/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
23.9%8/10

Revenue surging 23.9% year-over-year

NVS4 strengths · Avg: 9.3/10
Market CapQuality
$302.86B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
34.0%10/10

Strong operational efficiency at 34.0%

Return on EquityProfitability
26.9%9/10

Every $100 of equity generates 27 in profit

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

Areas to Watch

CSTL4 concerns · Avg: 2.5/10
Market CapQuality
$1.05B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-4.1%2/10

ROE of -4.1% — below average capital efficiency

EPS GrowthGrowth
-51.6%2/10

Earnings declined 51.6%

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.6x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CSTL

The strongest argument for CSTL centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 23.9% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.

Bear Case : CSTL

The primary concerns for CSTL are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Key Dynamics to Monitor

CSTL profiles as a growth stock while NVS is a value play — different risk/reward profiles.

CSTL carries more volatility with a beta of 0.95 — expect wider price swings.

CSTL is growing revenue faster at 23.9% — sustainability is the question.

NVS generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (48/100 vs 34/100), backed by strong 17.5% margins. CSTL offers better value entry with a 59.1% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Castle Biosciences Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests, particularly within the skin cancer sector, exemplified by its flagship product, DecisionDx®-Melanoma. This innovative test offers essential insights for risk stratification, enabling oncologists to make informed treatment decisions in managing melanoma. With a strong focus on precision medicine, coupled with an extensive research and development strategy, Castle Biosciences is poised for growth as it seeks to expand its offerings and meet critical clinical demands. By addressing the complexities inherent in oncology, the company not only aims to improve patient outcomes but also to generate substantial value for its investors.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?